Frederic T.
- Country
- France
- Department
- Neurologie
Research Overview
- Efficacy of Rituximab Versus Placebo in Anti-MAG Neuropathy Patients with Predicted Good Response: A Randomized Controlled Trial
- Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: An Open-label Extension Study
- Long-term Safety and Efficacy of Avalglucosidase Alfa in French Patients with Glycogen Storage Disease Type II: A Phase 4 Open-label Extension Study
Data & Insights
Has run more than one trial at 18 of 92 partner sites.
Specializations
Rare Metabolic Disorders
The investigator specializes in the treatment of Glycogen Storage Disease Type II, also known as Pompe disease. Their research focuses on innovative therapeutic approaches and long-term management strategies for patients with this rare genetic condition.
- Enzyme Replacement Therapy
- Long-term Disease Management
- Treatment Safety Assessment
Autoimmune Neuropathies
The investigator conducts research in anti-MAG neuropathy, focusing on targeted therapeutic interventions. Their work involves evaluating treatment responses and neurological disability improvements in patients with this specific autoimmune condition.
- Targeted Immunotherapy
- Neurological Disability Assessment
- Clinical Response Evaluation
Inflammatory Neurological Disorders
The investigator studies Chronic Inflammatory Demyelinating Polyneuropathy, with particular attention to novel therapeutic approaches. Their research encompasses long-term treatment outcomes and innovative administration methods for autoimmune disorders affecting peripheral nerves.
- Subcutaneous Therapeutics
- Long-term Safety Monitoring
- Autoimmune Disease Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.